期刊
EMBO MOLECULAR MEDICINE
卷 4, 期 10, 页码 1087-1096出版社
WILEY-BLACKWELL
DOI: 10.1002/emmm.201201250
关键词
breast cancer; NAMPT; PARP inhibitor; triple negative; beta-NAD(+)
资金
- Breakthrough Breast Cancer
- Cancer Research UK
- AACR as part of the Stand Up to Cancer Breast Cancer Dream Team
- NHS
PARP inhibitors have been proposed as a potential targeted therapy for patients with triple-negative (ER-, PR-, HER2-negative) breast cancers. However, it is as yet unclear as to whether single agent or combination therapy using PARP inhibitors would be most beneficial. To better understand the mechanisms that determine the response to PARP inhibitors, we investigated whether enzymes involved in metabolism of the PARP substrate, beta-NAD(+), might alter the response to a clinical PARP inhibitor. Using an olaparib sensitization screen in a triple-negative (TN) breast cancer model, we identified nicotinamide phosphoribosyltransferase (NAMPT) as a non-redundant modifier of olaparib response. NAMPT is a rate-limiting enzyme involved in the generation of the PARP substrate beta-NAD(+) and the suppression of beta-NAD(+) levels by NAMPT inhibition most likely explains these observations. Importantly, the combination of a NAMPT small molecule inhibitor, FK866, with olaparib inhibited TN breast tumour growth in vivo to a greater extent than either single agent alone suggesting that assessing NAMPT/PARP inhibitor combinations for the treatment of TN breast cancer may be warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据